Via PD-L1

O cancro utiliza a via PD-L1 para escapar à vigilância imunitária^1-5

Recursos no site:
Brochura sobre a via PD-L1

Descarregue

Referências

1. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumour immunity. Curr Opin Immunol.2012;24:207-212. Artigo Completo
2. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10. Artigo Completo
3. Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18:6580-6587. Artigo Completo
4. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. Artigo Completo
5. Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer.2013;108:1560-1565. Artigo Completo